FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W569503540> ?p ?o ?g. }

• W569503540 abstract "e14544 Background: BEV is potent inhibitor of VEGF-mediated tumor angiogenesis. VEGF is also crucial in antineoplastic immunortolerance by blocking the generation of dendritic cells (DC). VEGF inhibition may thus result in an improved anti-cancer immune response which may be further augmented by GM-CSF, a powerful stimulator of DC generation. In a previous study, GM-CSF was able to produce clinical responses in patients (pts) suffering from refractory carcinomas (Kurbacher et al., Oncology 2005). In this trial, we investigated BEV+GM-CSF in pts with advanced solid neoplasms. Methods: 26 pts have been enrolled: epithelial ovarian cancer, n=12; breast cancer, n= 6; primary peritoneal carcinoma, n=3; hormone-refractory prostate cancer, n=2; miscellaneous, n=3. All pts have been considered refractory to or non-treatable by chemotherapy due to their baseline bone marrow and/or organ functions. Fourteen pts had previously received BEV as part of other antineoplastic regimens. BEV was applied at a fixed dose of 6 mg/kg q2w. The starting dose of GM-CSF (sargramostim) was 125 μg/d. In cases not responding and/or not achieving moderate leukocytosis (< 20 G/L), GM-CSF was increased every 4 weeks at 25 μg increments up to a maximum of 250 μg/d. Toxicity was documented according to the NCI-CTC score, responses were recorded according to the RECIST or Rustin criteria. Results: Grade (G) 3–4 hypertension was seen in 3 pts, with 1 pt experiencing cerebral stroke 6 weeks after cessation of BEV+GM-CSF. Other G3–4 toxicities were fatigue in two pts, and fever, pain, myalgia, and central nervous symptoms in either one pt. Other side-effects like injection-site reactions, proteinuria, anemia, thrombocytopenia, and constipation did not exceed G1–2. The objective response rate was 31% (1 CR, 7 PR, 10 SD, and 8 PD); the rate of pts benefiting was 69%. Eight pts failing prior BEV benefited from BEV+GM-CSF. Until today, 13 pts have died. The median time to progression is 92 days and the median overall survival is 302 days. Conclusions: BEV+GM-CSF is an active and generally well tolerated non-cytotoxic regimen in pts with advanced solid tumors. Thus, large-scaled studies of this promising treatment are warranted. No significant financial relationships to disclose." @default.
• W569503540 created "2016-06-24" @default.
• W569503540 creator A5014400962 @default.
• W569503540 creator A5017884752 @default.
• W569503540 creator A5035245907 @default.
• W569503540 creator A5050907537 @default.
• W569503540 creator A5078554385 @default.
• W569503540 creator A5078912326 @default.
• W569503540 creator A5091155920 @default.
• W569503540 date "2009-05-20" @default.
• W569503540 modified "2023-09-25" @default.
• W569503540 title "Bevacizumab (BEV) and continuous low-dose granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid tumors: final results of a prospective clinical trial" @default.
• W569503540 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e14544" @default.
• W569503540 hasPublicationYear "2009" @default.
• W569503540 type Work @default.
• W569503540 sameAs 569503540 @default.
• W569503540 citedByCount "0" @default.
• W569503540 crossrefType "journal-article" @default.
• W569503540 hasAuthorship W569503540A5014400962 @default.
• W569503540 hasAuthorship W569503540A5017884752 @default.
• W569503540 hasAuthorship W569503540A5035245907 @default.
• W569503540 hasAuthorship W569503540A5050907537 @default.
• W569503540 hasAuthorship W569503540A5078554385 @default.
• W569503540 hasAuthorship W569503540A5078912326 @default.
• W569503540 hasAuthorship W569503540A5091155920 @default.
• W569503540 hasConcept C121608353 @default.
• W569503540 hasConcept C126322002 @default.
• W569503540 hasConcept C143998085 @default.
• W569503540 hasConcept C2776694085 @default.
• W569503540 hasConcept C2777478134 @default.
• W569503540 hasConcept C2777767877 @default.
• W569503540 hasConcept C2777802072 @default.
• W569503540 hasConcept C2777983669 @default.
• W569503540 hasConcept C2778690821 @default.
• W569503540 hasConcept C2993640289 @default.
• W569503540 hasConcept C535046627 @default.
• W569503540 hasConcept C71924100 @default.
• W569503540 hasConceptScore W569503540C121608353 @default.
• W569503540 hasConceptScore W569503540C126322002 @default.
• W569503540 hasConceptScore W569503540C143998085 @default.
• W569503540 hasConceptScore W569503540C2776694085 @default.
• W569503540 hasConceptScore W569503540C2777478134 @default.
• W569503540 hasConceptScore W569503540C2777767877 @default.
• W569503540 hasConceptScore W569503540C2777802072 @default.
• W569503540 hasConceptScore W569503540C2777983669 @default.
• W569503540 hasConceptScore W569503540C2778690821 @default.
• W569503540 hasConceptScore W569503540C2993640289 @default.
• W569503540 hasConceptScore W569503540C535046627 @default.
• W569503540 hasConceptScore W569503540C71924100 @default.
• W569503540 hasLocation W5695035401 @default.
• W569503540 hasOpenAccess W569503540 @default.
• W569503540 hasPrimaryLocation W5695035401 @default.
• W569503540 hasRelatedWork W1967773096 @default.
• W569503540 hasRelatedWork W1970007654 @default.
• W569503540 hasRelatedWork W1989553810 @default.
• W569503540 hasRelatedWork W1990281140 @default.
• W569503540 hasRelatedWork W2000117247 @default.
• W569503540 hasRelatedWork W2008312226 @default.
• W569503540 hasRelatedWork W2012393496 @default.
• W569503540 hasRelatedWork W2020759756 @default.
• W569503540 hasRelatedWork W2075582201 @default.
• W569503540 hasRelatedWork W2083801528 @default.
• W569503540 hasRelatedWork W2084405399 @default.
• W569503540 hasRelatedWork W2288798679 @default.
• W569503540 hasRelatedWork W2316750144 @default.
• W569503540 hasRelatedWork W2411171958 @default.
• W569503540 hasRelatedWork W2423631246 @default.
• W569503540 hasRelatedWork W2591472830 @default.
• W569503540 hasRelatedWork W2796422003 @default.
• W569503540 hasRelatedWork W2927097544 @default.
• W569503540 hasRelatedWork W3036376549 @default.
• W569503540 hasRelatedWork W3030324048 @default.
• W569503540 isParatext "false" @default.
• W569503540 isRetracted "false" @default.
• W569503540 magId "569503540" @default.
• W569503540 workType "article" @default.